ストックスクリーナーアプリを入手
1.46
3.55%
0.05
前日終値:
$1.41
開ける：
$1.43
24時間の取引高:
44,057
Relative Volume:
0.56
時価総額：
$48.10M
収益：
-
当期純損益:
$-34.26M
株価収益率:
-0.0772
EPS:
-18.9056
ネットキャッシュフロー:
$-15.62M
1週間 パフォーマンス:
+6.67%
1か月 パフォーマンス:
-31.75%
6か月 パフォーマンス:
-74.10%
1年 パフォーマンス:
-70.12%
1日の値動き範囲:
$1.41
$1.47
1週間の範囲:
$1.28
$1.54
52週間の値動き範囲:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
名前
Dogwood Therapeutics Inc
セクター
電話
(866) 620-8655
住所
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.44 | 48.10M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
705.22 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
798.92 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
302.01 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dogwood Therapeutics Inc (DWTX) 最新ニュース
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor By Investing.com - Investing.com Canada
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor - Investing.com
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today.Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval - Insider Monkey
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
Dogwood Therapeutics (DWTX) seeks approval to increase authorized shares to 195M - Stock Titan
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - Sahm
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com Australia
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest - MarketBeat
Dogwood Therapeutics receives FDA clearance for SP16 pain trial - Investing.com
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Decliners Report: How volatile is Dogwood Therapeutics Inc stock2026 Market WrapUp & AI Driven Stock Movement Reports - baoquankhu1.vn
Will Dogwood Therapeutics Inc benefit from government policyCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Investment Report: Will Dogwood Therapeutics Inc benefit from geopolitical trends2026 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-04-11 05:48:42 - baoquankhu1.vn
Activity Recap: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Is Dogwood (DWTX) Stock in a Downtrend | Price at $2.22, Up 5.21%Community Watchlist - Newser
Performance Recap: How sensitive is Dogwood Therapeutics Inc to inflationEarnings Summary Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Weekly: Should I invest in Dogwood Therapeutics Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Downgrade Watch: How sensitive is Dogwood Therapeutics Inc to inflationMarket Sentiment Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Sentiment Watch: What is the PEG ratio of Dogwood Therapeutics IncCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Dogwood Therapeutics Reports Q1 2026 Progress: Advances in Halneuron® and SP16 for Cancer-Related Pain and Neuropathy, $12.5M Raised - Minichart
Analysts Issue Forecasts for DWTX Q1 Earnings - Defense World
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway - TipRanks
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
Q1 Earnings Estimate for DWTX Issued By Zacks Research - MarketBeat
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - MarketBeat
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics Inc (DWTX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
2.09%
大文字化:
|
ボリューム (24 時間):